Advertisement

Advertisement

Hepatobiliary Cancer
Immunotherapy

Immunotherapy in Unresectable HCC With Child-Pugh Class B Dysfunction

In a retrospective study reported in JAMA Oncology, Fulgenzi et al found evidence that immune checkpoint inhibitor (ICI)-based treatment may improve survival vs best supportive care as first-line therapy in patients with unresectable hepatocellular carcinoma and Child-Pugh class B (CP-B) liver...

Colorectal Cancer
Immunotherapy

pMMR/MSS Locally Advanced Rectal Cancer: Immunotherapy-Based Total Neoadjuvant Therapy

In a Chinese phase II trial (TORCH) reported in the Journal of Clinical Oncology, Xia et al found that integration of the PD-1 inhibitor toripalimab into total neoadjuvant therapy was associated with good outcomes in patients with mismatch repair–proficient or microsatellite-stable (pMMR/MSS)...

Immunotherapy

Immunotherapy-Induced Multiorgan Immune-Related Adverse Events: Co-occurrence Patterns and Prognostic Implications

The results of a retrospective multicohort study, reported in The Lancet Oncology by Wan et al, suggested that the identification of the immune-related adverse event cluster to which a patient belongs may aid in prognosticating response to immunotherapy. “These insights can be leveraged to counsel...

breast cancer
immunotherapy

Heather McArthur, MD, MPH, on Immunotherapy for High-Risk, Early-Stage Breast Cancer

Heather McArthur, MD, MPH, talks about immunotherapy for high-risk, early-stage breast cancer. Dr. McArthur is Associate Professor in the Department of Internal Medicine and Clinical Director of the Breast Cancer Program at Simmons Cancer Center at UT Southwestern Medical Center, Houston. She presented her talk at the Annual International Congress on the Future of Breast Cancer West. 

Lymphoma
Immunotherapy

LBCL: CD22-Directed CAR T-Cell Therapy After Disease Progression on CD19-Directed CAR T-Cell Therapy

In a single-center phase I trial reported in The Lancet, Frank et al found that CD22-directed chimeric antigen receptor (CAR) T-cell therapy (CAR22) showed activity in patients with large B-cell lymphoma (LBCL) whose disease progressed on CD19-directed CAR T-cell therapy (CAR19). CD22 is a nearly...

Skin Cancer
Issues in Oncology
Immunotherapy

High-Risk Melanoma: Inhibiting MEK and PD-L1 in Tandem

Cobimetinib and atezolizumab administered prior to surgery eliminated or shrunk tumors in 70% of patients with melanoma enrolled in the NeoACTIVATE trial. Results were published by Hieken et al in Nature Communications. Background Melanoma of the skin is the fifth most common cancer type in the...

Solid Tumors
Colorectal Cancer
Immunotherapy

Novel Immunotherapy Approach in Metastatic Solid Tumors

A novel personalized cellular immunotherapy approach may be effective at treating certain patients with metastatic solid tumors, according to early findings from a recent study published by Parkhurst et al in Nature Medicine. Background Chimeric antigen receptor (CAR) T-cell therapy has already...

Pancreatic Cancer
Immunotherapy

Resected Pancreatic Cancer: Autologous Dendritic Cell Vaccination

In a Dutch single-center phase I/II study reported in the Journal of Clinical Oncology, van ‘t Land et al found that adjuvant autologous dendritic cell vaccination was associated with promising recurrence-free survival in patients who had undergone resection and standard-of-care treatments for...

Gastroesophageal Cancer
Immunotherapy

Pembrolizumab/Chemotherapy in First-Line Treatment of HER2-Negative Advanced Gastric or GEJ Adenocarcinoma

On November 16, 2023, pembrolizumab (Keytruda) was approved with fluoropyrimidine- and platinum-containing chemotherapy for first-line treatment of locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.1 Supporting Efficacy Data Approval ...

Lymphoma
Immunotherapy

Phase I Study in NHL: Use of ‘Armored’ CAR T Cells May Be Feasible After Standard CAR T-Cell Failure

A novel “armored” chimeric antigen receptor (CAR) T cell appears to be feasible for retreatment of patients with non-Hodgkin lymphoma (NHL) who fail to respond to standard CAR T-cell therapy, according to preliminary results of a phase I trial presented at the 2024 ASCO Annual Meeting.1 The unique...

Solid Tumors
Hematologic Malignancies
Immunotherapy

Risk of Secondary Cancer After CAR T-Cell Therapy

In a single-center study reported in The New England Journal of Medicine, Hamilton et al found that second tumors had occurred in 25 of 724 patients during 15 months of follow-up after receipt of chimeric antigen receptor (CAR) T-cell therapy, including one fatal case of T-cell lymphoma. The study...

Gynecologic Cancers
Immunotherapy

LEAP-001: Study Misses Endpoints but Still Shows Benefit for Lenvatinib/Pembrolizumab in Endometrial Cancer Subsets

The highly anticipated ENGOT-en9/LEAP-001 trial in endometrial cancer has missed both its primary endpoints. At the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer, the study investigators reported no significant benefit in progression-free survival or overall survival...

Skin Cancer
Immunotherapy

NADINA Trial Shows Robust Benefit for Neoadjuvant Nivolumab Plus Ipilimumab in Stage III Melanoma

Results of the phase III NADINA trial support a new standard of care for the treatment of resectable macroscopic stage III melanoma. Treatment with preoperative ipilimumab plus nivolumab followed by total lymph node dissection, with adjuvant therapy guided by depth of response, led to a highly...

Sarcoma
Immunotherapy

Can Pembrolizumab Improve Outcomes in Soft-Tissue Sarcoma?

The PD-1 inhibitor pembrolizumab may offer benefit in patients with soft-tissue sarcoma, according to recent findings presented by Mowery et al at the 2024 ASCO Annual Meeting (Abstract 11504). Background Soft-tissue sarcoma is a rare type of cancer affecting muscles, fat, and other connective...

Colorectal Cancer
Immunotherapy
Genomics/Genetics

Neoadjuvant Pembrolizumab May Improve Outcomes in Some Patients With Colorectal Cancer Surgery

Researchers examined whether the PD-1 inhibitor pembrolizumab given neoadjuvantly may improve outcomes in certain patients with stage II or III mismatch repair–deficient/microsatellite instability–high colorectal cancer. Interim findings from the phase II NEOPRISM-CRC clinical trial were presented...

Lymphoma
Issues in Oncology
Immunotherapy

Novel CAR T-Cell Therapy Under Study in Relapsed or Refractory Non-Hodgkin Lymphoma

A novel “armored” type of chimeric antigen receptor (CAR) T-cell therapy called huCART19-IL18 may prove to be effective in patients with non-Hodgkin lymphoma who do not respond to standard CAR T-cell therapy, according to recent findings from a phase I clinical trial presented by Svoboda et al at...

leukemia
immunotherapy

Allison M. Winter, MD, on Richter Transformation: New Data on a CAR T-Cell Treatment

Allison M. Winter, MD, of the Cleveland Clinic Taussig Cancer Institute, discusses real-world outcomes with lisocabtagene maraleucel in patients with Richter transformation, a difficult-to-treat population with a poor prognosis. Data from the Center for International Blood and Marrow Transplant Research showed this therapy provided clinical benefit with a high complete response rate (Abstract 7010).

Skin Cancer
Immunotherapy

Neoadjuvant Immunotherapy Combination Improves Outcomes in Patients With Melanoma

Neoadjuvant immunotherapy given for stage III melanoma—followed by adjuvant therapy only if there is not a deep response to treatment—may produce better outcomes for patients than the current standard of care, which is adjuvant immunotherapy alone. These results from the NADINA trial were presented ...

Lymphoma
Immunotherapy

CAR T-Cell Therapy in Patients With Central Nervous System Lymphoma

A chimeric antigen receptor (CAR) T-cell therapy approved for patients with large B-cell lymphoma has produced positive results in a pilot study involving patients with relapsed, treatment-resistant central nervous system (CNS) lymphoma. These findings from a small cohort were presented by Nayak et ...

Leukemia
Immunotherapy

Relapsed or Refractory B-Cell ALL: Novel CAR T-Cell Therapy Yields Strong Remission Rates

The novel anti-CD19 autologous chimeric antigen receptor (CAR) T-cell therapy obecabtagene autoleucel achieved durable remissions in 40% of patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) without a subsequent stem cell transplant, according to results from the phase...

Colorectal Cancer
Immunotherapy

Can a Novel Combination Therapy Improve Metastatic Colorectal Cancer Outcomes?

A novel combination comprising experimental immunotherapy drugs plus chemotherapy may improve survival outcomes in previously treated patients with metastatic colorectal cancer compared to the targeted therapy regorafenib alone. These findings will be presented by Wainberg et al at the 2024 ASCO...

Immunotherapy

Introducing ASPIRE and STORIES: A New International Initiative for Faculty Collaboration and Patient Advocacy in Immune-Related Adverse Events

The Immune-Related Adverse Events (irAE) Consortium has launched ASPIRE and STORIES with the aim of uniting clinicians, researchers, and patients to advance clinical care and advocacy. As the indications for immune checkpoint inhibitors in oncology have rapidly expanded over the past decade, the...

Kidney Cancer
Immunotherapy

CRISPR-Edited, Off-the-Shelf CAR T-Cell Therapy Shows Proof of Concept in Renal Cell Carcinoma

Evidence from a small early trial called COBALT-RCC provides proof of concept for use of an allogeneic off-the-shelf CD70-targeted chimeric antigen receptor (CAR) T-cell therapy called CTX130 in patients with advanced clear cell renal cell carcinoma (RCC). CTX130 is engineered using gene-editing...

Bladder Cancer
Immunotherapy

Nivolumab/Ipilimumab Boost in Metastatic Urothelial Carcinoma

In a German-Austrian phase II study (TITAN-TCC) reported in JAMA Oncology, Grimm et al described outcomes with the use of nivolumab plus ipilimumab as an immunotherapeutic boost in metastatic urothelial carcinoma. Study Details In the multicenter trial, 169 patients were enrolled into two cohorts...

Lymphoma
Immunotherapy

FDA Grants Accelerated Approval to Lisocabtagene Maraleucel for Relapsed or Refractory Follicular Lymphoma

On May 15, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (Breyanzi) for adult patients with relapsed or refractory follicular lymphoma who have received two or more prior lines of systemic...

Immunotherapy

KEYNOTE-756 Additional Findings: Pembrolizumab Shown to Be Beneficial Regardless of Age, Menopausal Status

In updated findings from the phase III KEYNOTE-756 trial, the addition of pembrolizumab to chemotherapy in the neoadjuvant setting improved the rates of pathologic complete response for patients with high-risk estrogen receptor–positive, HER2-negative breast cancer, regardless of their age or...

Hepatobiliary Cancer
Immunotherapy

Bavituximab Plus Pembrolizumab for Patients With Hepatocellular Carcinoma

Adding the phosphatidylserine-targeting antibody bavituximab to the immunotherapy agent pembrolizumab may improve response rates without compromising safety in patients with hepatocellular carcinoma, according to a recent study published by Hsieh et al in Nature Communications. The findings...

Leukemia
Lymphoma
Immunotherapy

Relapsed or Refractory CD7-Positive Leukemia or Lymphoma: CAR T-Cell Therapy Plus HSCT Without GVHD Prophylaxis

In a Chinese study reported in The New England Journal of Medicine, Hu et al found that sequential CD7 chimeric antigen receptor (CAR) T-cell therapy and allogeneic hematopoietic stem cell transplantation (HSCT) without graft-vs-host disease (GVHD) prophylaxis was effective in patients with...

Prostate Cancer
Immunotherapy
Supportive Care

Combination of Preketone Supplements and Immunotherapy May Be Effective in Patients With Prostate Cancer

The addition of a component of the ketogenic diet—a preketone dietary supplement—to immunotherapy showed efficacy in potentially treating prostate cancer in a laboratory setting, according to a recent study published by Murphy et al in Cancer Research. Background Although immune checkpoint blockade ...

Hematologic Malignancies
Immunotherapy

Risk of T-Cell and Second Primary Malignant Neoplasms After CAR T-Cell Therapy

In a study reported in a research letter in JAMA Oncology, Storgard et al identified the risk of T-cell malignant neoplasms and any second primary malignant neoplasms in patients receiving chimeric antigen receptor (CAR) T-cell therapy for hematologic malignancies. Study Details   The study used...

skin cancer
immunotherapy

Sophia McKinley, MD, EdM, on Cutaneous Melanoma: Outcomes With Adjuvant Immunotherapy

Sophia McKinley, MD, EdM, of Massachusetts General Hospital, discusses patterns of recurrence in patients with resected cutaneous melanoma during or after adjuvant immunotherapy. She identifies the risk factors associated with overall survival and treatment failure (Abstract 60).

Skin Cancer
Immunotherapy
Issues in Oncology

Immunotherapy Resistance and Response to Adoptive Therapy in Patients With Metastatic Uveal Melanoma

Researchers may have uncovered the mechanisms behind conventional immunotherapy resistance as well as the efficacy of adoptive therapy in metastatic uveal melanoma, according to a recent study published by Leonard-Murali et al in Nature Communications. The findings demonstrated the potential to...

skin cancer
immunotherapy

Jenny H. Chang, MD, on New Findings on Merkel Cell Carcinoma and Neoadjuvant Immunotherapy

Jenny H. Chang, MD, of the Cleveland Clinic, discusses the current surgical and radiologic treatment paradigm for patients with stage III Merkel cell carcinoma and the potential for neoadjuvant immunotherapy to help manage the disease and regional lymph node metastases (Abstract 67).

Leukemia
Immunotherapy

Anti-CD19 CAR T-Cell Therapy for Richter Transformation

In a retrospective study reported in the Journal of Clinical Oncology, Kittai et al found that anti-CD19 chimeric antigen receptor (CAR) T-cell therapy showed activity in previously treated patients with Richter transformation. Study Details In the study, 69 patients who received CAR T-cell therapy ...

Prostate Cancer
Immunotherapy

Biologic Drug-Device Combination Immunotherapy in Metastatic Prostate Cancer

SYNC-T—an investigational therapy that combines a device-induced vaccination at the tumor site with an intratumoral infusion of a multitarget biologic drug—led to numerous clinical responses in patients with metastatic castration-resistant prostate cancer, according to results reported at the...

Gastroesophageal Cancer
Gastrointestinal Cancer
Immunotherapy

Bispecific Immune Checkpoint Inhibitor Improves Survival in Patients With Gastric Cancer, Regardless of PD-L1 Status

The PD-1/CTLA-4 bispecific antibody cadonilimab plus chemotherapy improved progression-free and overall survival in patients with untreated, HER2-negative, locally advanced or metastatic gastric or gastroesophageal junction (GEJ) cancer—including those with PD-L1–low tumors—compared with...

Skin Cancer
Immunotherapy

RP1 Immunotherapy in Solid Organ Transplant Recipients With Skin Cancer

A novel oncolytic immunotherapy may show antitumor activity in solid organ transplant recipients with skin cancer, according to new findings presented by Migden et al at the American Association for Cancer Research (AACR) Annual Meeting 2024 (Abstract CT003). Background "Organ transplant recipients ...

Kidney Cancer
Immunotherapy

Novel CAR T-Cell Therapy May Show Benefit in Patients With Advanced Clear Cell Renal Cell Carcinoma

The CD70-targeted allogeneic chimeric antigen receptor (CAR) T-cell therapy CTX130 may be effective in patients with advanced clear cell renal cell carcinoma, according to findings presented by Srour et al at the American Association for Cancer Research (AACR) Annual Meeting 2024 (Abstract CT002)...

Gynecologic Cancers
Immunotherapy

Mirvetuximab Soravtansine Plus Pembrolizumab in Patients With Endometrial Cancer Subtype

The combination of the antibody-drug conjugate mirvetuximab soravtansine-gynx and the immune checkpoint inhibitor pembrolizumab showed notable activity in patients with recurrent or persistent microsatellite-stable endometrial cancer, according to new findings presented by Porter et al at the...

Hepatobiliary Cancer
Immunotherapy

Can a Personalized Antitumor Vaccine Plus Pembrolizumab Improve Outcomes in Hepatocellular Carcinoma?

Adding a personalized antitumor vaccine to the PD-1 inhibitor pembrolizumab may be safe and about twice as effective at shrinking tumors in patients with hepatocellular carcinoma compared with pembrolizumab alone, according to new findings presented by Yarchoan et al at the American Association for ...

Bladder Cancer
Immunotherapy
Issues in Oncology

Improving Adjuvant Treatment in Patients With Muscle-Invasive Urothelial Carcinoma

Two recent studies have offered new insights into the treatment of muscle-invasive urothelial carcinoma following cystectomy, according to findings presented by Powles et al and Galsky et al at the European Association of Urology Congress 2024. The research could allow physicians to target...

Sarcoma
Immunotherapy

T-Cell Therapy in Advanced Synovial Sarcoma and Myxoid Round Cell Liposarcoma

In a phase II trial (SPEARHEAD-1) reported in The Lancet, D’Angelo et al found that the T-cell therapy afamitresgene autoleucel showed activity in patients with previously treated HLA-A*02 and MAGE-A4–expressing advanced synovial sarcoma or myxoid round cell liposarcoma. As related by the...

Immunotherapy
Lung Cancer

Amivantamab-vmjw in NSCLC With EGFR Exon 20 Insertion Mutations

On March 1, 2024, amivantamab-vmjw (Rybrevant) was approved for use with carboplatin and pemetrexed for first-line treatment of locally advanced or metastatic non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, as detected by a U.S. Food and Drug Administration (FDA)-approved...

Hematologic Malignancies
Immunotherapy
Issues in Oncology

Incidence of Secondary T-Cell Malignancies Following CAR T-Cell Therapy

Investigators have found that second primary malignancies following chimeric antigen receptor (CAR) T-cell therapy were reported in 4.3% of CAR T-cell therapy adverse event reports submitted to the U.S. Food and Drug Administration’s (FDA) Adverse Event Reporting System, with T-cell malignancies...

Breast Cancer
Immunotherapy

Updated Immune Classifier May Accurately Identify Patients With Triple-Negative Breast Cancer Who Are Unlikely to Respond to Immunotherapy

A novel genetic test may predict how patients with triple-negative early-stage breast cancer will respond to immunotherapy, according to new findings presented by Wolf et al at the 2024 European Breast Cancer Conference (EBCC) (Abstract 2LBA). The research may help patients who are unlikely to...

Breast Cancer
Immunotherapy

Pembrolizumab May Improve Breast Cancer Outcomes Regardless of Age or Menopausal Status

The addition of the immunotherapy drug pembrolizumab to chemotherapy prior to and following surgery may lead to improved outcomes in patients with breast cancer regardless of their age or menopausal status, according to new findings presented by Cardoso et al at the 2024 European Breast Cancer...

Immunotherapy
Symptom Management

CAR T-Cell Therapy Complications: Comparison of Three Testing Modalities

Magnetic resonance imaging (MRI) and lumbar puncture may not always be necessary for diagnosing and managing a serious neurologic complication associated with chimeric antigen receptor (CAR) T-cell therapy, according to a new study published by Mauget et al in Blood Advances. Findings further...

Immunotherapy
Lung Cancer

Use of Combination Immunotherapy Before Lung Cancer Surgery

Combination immunotherapy with the anti–PD-L1 monoclonal antibody durvalumab and other novel agents seemed to outperform durvalumab alone in the neoadjuvant setting for early-stage non–small cell lung cancer (NSCLC), according to researchers from The University of Texas MD Anderson Cancer Center,...

Gastroesophageal Cancer
Immunotherapy

Liquid Biopsy May Help Predict Outcomes in Patients With Gastroesophageal Cancers Following Immunotherapy

Monitoring circulating tumor DNA (ctDNA) levels with liquid biopsies could help physicians accurately assess treatment responses and predict future prognoses in patients with operable esophageal or gastroesophageal junction cancer receiving an immunotherapy doublet, according to a recent study...

Leukemia
Lymphoma
Immunotherapy

Accelerated Approval Granted to First CAR T-Cell Therapy for Relapsed or Refractory CLL/SLL

On March 14, the U.S. Food and Drug Administration (FDA) granted accelerated approval to lisocabtagene maraleucel (Breyanzi), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, for the treatment of adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small...

Advertisement

Advertisement

Advertisement